Company continues to improve its market position as it nears launch of its Phase 1 clinical trial in AML SOUTH SAN FRANSCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces an agreement with the University of California Davis for the manufacturing of CER-1236 to be used in the Company’ ...

SOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it is presenting encouraging preclinical results of lead compound CER-1236 in ovarian cancer during the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors in San Diego, March 12-14. In the poster, titled, “T ...

Core Insights - CERo Therapeutics Holdings, Inc. is presenting promising preclinical results for its lead compound CER-1236 in ovarian cancer at the 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors [1][2] - The study demonstrated that CER-1236 effectively targets ovarian cancer cells without causing toxicity in animal models, indicating a favorable safety profile [2][3] - The company plans to initiate clinical trials for CER-1236 in solid tumors in 2025, building on its previous findings in both ovarian and Non-Small Cell Lung Cancers (NSCLC) [3][4] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, utilizing a proprietary approach that combines innate and adaptive immunity [4] - The company’s Chimeric Engulfment Receptor T cells (CER-T) are designed to enhance the immune response against tumors, potentially offering broader therapeutic applications than current CAR-T therapies [4]

Core Insights - CERo Therapeutics is advancing its Phase 1 clinical trial for CER-1236 targeting Acute Myeloid Leukemia (AML) [1][2] - The company has partnered with CellCarta to manage translational assays and logistics for the trial [1][2] - CERo's innovative approach integrates innate and adaptive immunity in engineered T cell therapeutics, potentially offering broader applications than current CAR-T therapies [3] Group 1: Clinical Trial Progress - The company is preparing to enroll patients in its Phase 1 clinical trial, with key data elements being managed by CellCarta [1][2] - Sample collection and testing are critical for obtaining essential data beyond safety in liquid tumors [2] Group 2: Company Overview - CERo Therapeutics focuses on engineered T cell therapeutics for cancer treatment, utilizing a novel cellular immunotherapy platform [3] - The company aims to redirect patient-derived T cells to eliminate tumors through phagocytic mechanisms, creating Chimeric Engulfment Receptor T cells (CER-T) [3] - CERo anticipates initiating clinical trials for CER-1236 in 2025, targeting hematological malignancies [3]

New poster to highlight preclinical data of CER-1236 in ovarian cancer SOUTH SAN FRANSCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it will be presenting preclinical results of lead compound CER-1236 in ovarian cancer during the Spring Scientific from the Society for Immunothera ...

Increased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 SOUTH SAN FRANSCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides investors with a corporate update highlighting its improved cash balance following its recent capital raise ...

SOUTH SAN FRANSCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced the pricing of its "reasonable best efforts" public offering with participation from a member of the Company's board and a single institutional investor for the purchase and sale of 2,551,020 shares of its common s ...

SOUTH SAN FRANSCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, today announced that its board of directors has determined to effect a one-for-one hundred reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The reverse stock split will take eff ...

Stock Issuance and Financing Activities - The company issued an aggregate of 7,597,638 shares of Common Stock as consideration for the Merger, including 2,200,000 Earnout Shares and 382,651 shares issuable upon exercise of rollover options or warrants[174] - In February 2024, the company completed the first tranche of a private placement, raising approximately $10.0 million through the issuance of Series A Preferred Stock and warrants[175] - In April 2024, the company raised approximately $0.5 million through a private placement of Series B Preferred Stock[176] - In September 2024, the company raised approximately $1.25 million through a private placement of Series C Preferred Stock and common warrants[177] - Net cash provided by financing activities increased by $11.7 million from $0.6 million in the nine-month period ended September 30, 2023 to $12.2 million in the nine-month period ended September 30, 2024[223] - The increase in cash provided by financing activities was related to the net proceeds of $7.3 million from the issuance of Series A and B Preferred Stock, $0.7 million from the issuance of Series C Preferred Stock and associated warrants, and $4.3 million for the sale of common stock under the ELOC[223] Clinical Development and Regulatory Progress - The company submitted an Investigational New Drug Application (IND) for CER-1236 on June 28, 2024, and received FDA clearance on November 15, 2024, with plans to initiate clinical trials by early 2025[178][179] Financial Performance and Expenses - The company has not recognized any revenue and does not expect to generate revenue from product sales in the foreseeable future[190] - R&D expenses are expected to increase significantly as the company advances its product candidates through clinical development[194] - General and administrative expenses are anticipated to rise due to increased headcount, operational support, and compliance costs associated with being a public company[196] - Research and development expenses increased to $1.8 million for the three-month period ended September 30, 2024, up from $1.3 million in the same period in 2023, reflecting a $0.5 million increase[202] - General and administrative expenses rose to $2.6 million for the three-month period ended September 30, 2024, compared to $0.3 million in the same period in 2023, a $2.4 million increase primarily due to public company operational costs[201] - Net loss for the three-month period ended September 30, 2024, was $4.2 million, compared to $1.3 million in the same period in 2023, reflecting a $2.9 million increase in losses[200] - Research and development expenses for the nine-month period ended September 30, 2024, were $6.2 million, up from $4.3 million in the same period in 2023, a $1.9 million increase[211] - General and administrative expenses for the nine-month period ended September 30, 2024, were $7.9 million, compared to $2.3 million in the same period in 2023, a $5.7 million increase driven by public company compliance costs[209] - Net loss for the nine-month period ended September 30, 2024, was $9.0 million, compared to $6.0 million in the same period in 2023, reflecting a $3.0 million increase in losses[208] - The company anticipates significant future increases in R&D expenses due to expanded headcount, compensation, and contracted services for preclinical and clinical development[203][212] - Other income for the nine-month period ended September 30, 2024, was $5.1 million, compared to $0.5 million in the same period in 2023, primarily due to a $4.7 million change in the value of the company's Earnout Liability[213] - Net cash used in operating activities increased by $6.6 million from $4.8 million to $11.4 million in the nine-month period ended September 30, 2023 and 2024 respectively[221] - The increase in cash used in operating activities was largely related to a $4.8 million increase in the adjustment to net loss related to the gain on the revaluation of derivative liabilities[221] Cash Position and Funding Needs - The company had $3.4 million in cash, restricted cash, and cash equivalents as of September 30, 2024, and expects to need substantial additional funding to support operations[216] - The company does not expect to generate revenue for at least the next few years and relies on additional financing to achieve its business objectives[214][219] Market and Regulatory Risks - The company received Nasdaq notices of non-compliance due to the Common Stock's bid price falling below $1.00 and the Market Value of Publicly Held Shares (MVPHS) falling below $15,000,000[180][182] - The company's stockholders approved a reverse stock split ranging from 1:25 to 1:150, with the Board of Directors authorizing a 1:40 reverse stock split expected to be effective around November 2024[186] - The company's primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates[239] - The company may be subject to fluctuations in foreign currency rates in the future if it contracts with vendors invoicing in a foreign denominated currency[240] - Inflation may materially impact the company in later periods of 2024 and beyond by increasing the cost of labor and costs associated with preclinical and clinical trials and future manufacturing and commercialization activities[241] Emerging Growth Company Status - The company is an emerging growth company and may take advantage of reduced disclosure and other requirements applicable to public companies[243] - The company expects to continue to take advantage of the benefits of the extended transition period for complying with new or revised accounting standards[243] - The company may cease to qualify as an emerging growth company if it exceeds $1.07 billion in total annual gross revenues or if the market value of its Common Stock held by non-affiliates exceeds $700.0 million[245]

SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) --  CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics augmented with phagocytic mechanisms derived from the innate arm of the immune system, announces that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug Application (IND) for Phase 1 clinical trials of its lead compound, CER-1236, in acut ...